You just read:

Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer

News provided by

Nektar Therapeutics

Jan 14, 2014, 08:15 EST